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Brain tumours comprise 2% of all malignant neoplasms in
adults in England and Wales, with some 4000 new cases and
3000 deaths each year. Incidence has increased by approximately
25% since 1971 in England and Wales (Quinn et al, 2001).
Similar increases have been seen in other western countries
(Muir et al, 1994). Brain tumours are 20–50% more common in
men. Incidence was approximately 25% higher in the most affluent
fifth of the population in England and Wales than in the
most deprived fifth during 1991–1993 (Quinn et al, 2001).
The cause of most brain tumours is unknown. Ionising radiation
is the only established cause, although some nitrosamines may be a
risk factor (Preston-Martin, 1996). Inherited syndromes may
account for 5% of cases. Acquired immunosuppression may increase
the risk of cerebral lymphoma. Occupations that have been linked to
increased risk include the petrochemical and rubber industries,
agricultural work, the nuclear industry and work involving exposure
to electromagnetic fields (Preston-Martin et al, 2006).
Only tumours of the brain explicitly coded as primary, malignant
(behaviour code 3) tumours were included here. Patients previously
registered with another primary malignancy at any time since 1971
were excluded. Brain tumours coded as benign (behaviour code 0) or
of uncertain or unspecified behaviour (behaviour code 1) are often
considered together with malignant tumours (Muir et al, 1994), and
approximately 10900 such brain tumours were recorded in the
National Cancer Registry during the period 1986–1999, approxi-
mately 20% of all recorded brain tumours in all regions of England
and Wales (data not shown). These tumours were not considered
eligible for analysis. It can be difficult to distinguish primary
tumours of the brain from metastases of primary tumours in other
organs, which are common, but tumours coded as metastatic
(behaviour code 6) were excluded. Malignant tumours of the cranial
nerves and spinal cord were also excluded.
The survival analyses reported here are based on the data for
37917 adults (aged 15–99 years) who were registered with a first,
primary, malignant tumour of the brain in England and Wales during
the period 1986–1999 and followed up to the end of 2001. These
patients represented approximately 86% of those eligible for analysis.
For 1.9%, the vital status was unknown on 5 November 2002 when the
data were extracted for analysis, and they were excluded. Patients
whose brain tumour was not their first primary malignancy (1.8%)
were also excluded. Most of the other exclusions were for a recorded
survival time of zero (date of diagnosis same as date of death; 9.8% of
c a s e s ) .S o m eo ft h e s ep a t i e n t sm a yh a v ed i e do nt h ed a yo fd i a g n o s i s ,
but many are likely to have been registered from a death certificate
only (DCO) (data not shown), and the two groups could not be
distinguished in these data. As the date of diagnosis and thus the
duration of survival are not available from a death certificate, both
categories were excluded. Such patients may well have shorter than
average survival (Berrino et al, 1995); hence, their exclusion may have
caused slight overestimation of overall survival. However, the propor-
tion of DCO cases was similar between deprivation groups and stable
over time; hence, their exclusion is unlikely to have caused bias in the
estimates of trends in survival, or of socioeconomic gradients.
During the 1990s, some 50% of brain tumours were specified as
arising in the frontal, parietal, temporal or occipital lobes, and only
3% arose in the cerebellum or brain stem, but the site was poorly
specified or unspecified for 42% of tumours. The proportions are
similar to those for the 1980s (Coleman et al, 1999).
Gliomas represented 87% of the tumours, mainly malignant
glioma (52%) and astrocytoma (30%). Morphology was ill-defined
or undefined for approximately 11%.
SURVIVAL TRENDS
Overall survival from tumours of the brain was either stable, or
actually fell, in both sexes, between the late 1980s and the late
1990s, reaching 28–30% at 1 year and 12–14% at 5 years (Table 1,
Figure 1). The decline in 5-year survival was more marked among
men: a statistically significant average change of  3% every 5
years, after adjustment for deprivation. Survival is generally 1–2%
higher for women.
Short-term predictions of survival, based on hybrid analysis
(Brenner and Rachet, 2004) of the survival probabilities
observed during 2000–2001, suggest that this decline may
shortly level off, or may even reverse and become positive.
Survival would then be expected once again to reach levels similar
to those seen for patients diagnosed during 1986–1990, some
10–15 years earlier, at approximately 29–31% at 1 year and
11–14% at 5 years (Table 1).
DEPRIVATION
For patients diagnosed during 1986–1990, survival up to 10
years after diagnosis was not significantly different among
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adults – the general pattern was one of slightly lower survival
among patients in the more deprived groups, particularly at 1 year
after diagnosis (Table 2).
Among men, the slight but significant decline in 5-year survival
(Table 1) was particularly marked among the most affluent groups
(Figure 2), leading to an actual reversal of the deprivation gradient
during the 1990s, with 5-year survival in the most deprived groups
some 3% higher than in the most affluent groups among men
diagnosed during 1996–1999 (Table 2). Flattening (or even
reversal) of the deprivation gap in survival was observed at all
intervals up to 10 years after diagnosis. For 5-year survival, the
average change in the deprivation gradient was statistically
significant at þ2.5% every 5 years in favour of the most deprived
groups. No such change occurred among women.
Short-term predictions of survival derived from the
data for 2000–2001 suggest that these trends may be levelling
off, with little further change in the socioeconomic difference in
survival.
COMMENT
The absence of any improvement in survival from brain tumours
in adults between 1986 and 1999, for either sex, represents a rare
exception to the general trend in cancer survival in England and
Wales during this period. For brain tumours, the overall trend is
in fact towards a decline in survival in both sexes, which is
statistically significant for 5-year survival among men ( 3% every
5 years). Hybrid analysis suggests that this decline may soon tail
off, or even revert to an increase, but the recent decline still stands
in sharp contrast to survival trends for brain tumours in both sexes
between the early 1970s and the late 1980s; over this 20-year
period, there was a steady increase in relative survival of 2–3%
every 5 years from approximately 21 to 30% at 1 year and from 9 to
14% at 5 years (Coleman et al, 1999).
Among brain tumour patients diagnosed in the 1970s and 1980s
in England and Wales, survival at 1 and 5 years was generally
lower among more deprived groups, even if the individual
differences were small, and not always statistically significant.
The flattening of the deprivation gradient in survival for both
sexes during the 1990s – and the clear reversal among men – thus
provides another striking exception to the general pattern seen for
other malignancies.
The trends in survival and in the socioeconomic differences
in survival may have a common explanation. The gradual
introduction of sensitive new diagnostic techniques, such as
computed tomography in the 1970s and magnetic resonance
imaging from the 1980s (Husband and Reznek, 2004), as well as
stereotactic biopsy, may have led to improved diagnosis, registra-
tion and classification of brain tumours, particularly among the
elderly (Swerdlow et al, 2001). If the general improvement in
diagnosis from noninvasive imaging had also been more marked
among the higher socioeconomic groups, the downward trend in
survival and the reversal of the deprivation gap in survival
reported here, could reflect improved diagnosis of lethal tumours
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years













1 year Men 30.2 (29.1, 31.3) 30.6 (29.6, 31.6) 30.4 (29.3, 31.5)  0.7 ( 2.7, 1.4) 30.7 (29.1, 32.2)
Women 30.9 (29.6, 32.2) 30.3 (29.1, 31.5) 28.8 (27.5, 30.1)  0.5 ( 2.9, 2.0) 29.1 (27.3, 30.9)
5 years Men 13.6 (12.8, 14.5) 13.0 (12.3, 13.8) 11.6 (10.7, 12.5)  3.1** ( 4.7,  1.4) 11.4 (10.4, 12.5)
Women 15.9 (14.9, 17.0) 14.6 (13.7, 15.6) 14.0 (12.9, 15.1)  0.8 ( 2.9, 1.2) 13.5 (12.2, 14.9)
10 years Men 9.2 (8.5, 10.0) 8.4 (7.8, 9.2)  2.0 ( 4.5, 0.4) 7.5 (6.6, 8.4)
Women 10.7 (9.8, 11.6) 10.1 (9.3, 11.0)  0.3 ( 3.4, 2.8) 9.3 (8.2, 10.5)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).















































































Figure 1 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed 1986–1999 and followed up to 2001. Survival estimated with
cohort or complete approach (1986–1990, 1991–1995, 1996–1999) or
hybrid approach (2000–2001) (see Rachet et al, 2008).
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more affluent groups (Greenwald et al, 1981).
We hypothesised that before widespread access to advanced
imaging techniques, some patients presenting as a neurological
emergency might have been diagnosed with stroke or cerebral
metastases, instead of primary cerebral tumour (MacVicar, 2004).
Information on diagnostic investigations for each patient was
not available in cancer registry data; however, to explore this
possibility, we analysed trends in the incidence of brain tumours
by deprivation group and duration of survival. The incidence
of brain tumours with survival up to 1 year increased by nearly a
third among men in the most affluent groups between 1986
and 1995, but remained stable for men in the most deprived
category until 1995. In contrast, trends in the incidence of
brain tumours with survival greater than 1 year hardly differed
between men in affluent and deprived groups. For women,
incidence trends between 1986 and 1999 were very similar in all
deprivation groups, and the deprivation gap in survival has not
changed significantly over the same time period either. The
differential trends in the incidence by deprivation group, lethality
and sex seem to be commensurate with the observed trends in
survival.
It is thus possible that the apparent decrease in survival from
brain tumours in adults of both sexes, and the reversal of the
deprivation gap in men, as well as the increase in incidence,
especially of patients with poor survival, may be the result of
diagnostic exclusion of stroke and cerebral metastases from
malignancy in other organs, and improved diagnosis of lethal
primary malignancy of the brain. It remains unclear why such a
diagnostic shift should affect men more than women.
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Figure 2 Trends in the deprivation gap in 5-year relative survival (%) by sex and calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001.
Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years




gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men  2.1 ( 5.3, 1.0) 0.4 ( 2.5, 3.3)  0.3 ( 3.5, 2.9) 1.0 ( 1.4, 3.4)  2.4 ( 6.9, 2.1)
Women  2.7 ( 6.4, 1.1)  3.5* ( 6.8,  0.1)  4.1* ( 7.8,  0.4)  0.8 ( 3.5, 2.0)  4.1 ( 9.3, 1.2)
5 years Men  1.8 ( 4.2, 0.6) 3.7** (1.5, 5.8) 2.6 ( 0.1, 5.2) 2.5** (0.6, 4.4) 1.5 ( 1.5, 4.5)
Women  0.8 ( 3.8, 2.2)  0.8 ( 3.3, 1.7)  1.4 ( 4.6, 1.9)  0.3 ( 2.6, 2.0)  0.8 ( 4.7, 3.1)
10 years Men 0.6 ( 1.5, 2.7) 2.1* (0.1, 4.1) 1.5 ( 1.4, 4.4) 0.5 ( 2.0, 3.0)
Women 0.0 ( 2.6, 2.5)  0.4 ( 2.8, 2.0)  0.3 ( 3.8, 3.2)  0.4 ( 3.7, 3.0)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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